Effects of XXXX and @entity3303 in a @entity235 model of sudden coronary death.

@entity63 @entity235 @entity1855 @entity3303 @entity2224 @entity583 @entity943
The efficacy of @entity1855 and @entity3303 for treating @entity63 -induced @entity943 was determined in a conscious @entity235 model with a previous @entity583 remote from the @entity63 area. Temporary (up to 5.5 minutes) occlusion of the circumflex coronary artery was made in eight conscious @entity235 that had sustained an @entity583 13 to 35 days previously. Each @entity235 served as its own control. @entity943 were observed in 100% of control experiments but in only 25% of experiments after @entity1855 pretreatment at 0.4 mg/kg body weight. Repetitive ventricular complexes, defined as two or more consecutive ventricular complexes terminating spontaneously in sinus rhythm, were seen in 88% of control experiments and 13% of @entity1855 experiments, whereas @entity2224 was seen in 6% of control experiments but in no @entity1855 experiment. Thus, @entity1855 abolished @entity943 or reduced the grade of @entity943 in all @entity235 . Six of the eight @entity235 were also tested with @entity3303 pretreatment at one or two doses resulting in mean plasma levels of 3.8 +/- 2.0 micrograms/ml. @entity943 were seen in 92% of control experiments and 100% of @entity3303 experiments. The incidence of @entity2224 increased from 8% in control to 60% in @entity3303 experiments. It is concluded that @entity1855 may prevent severe @entity63 -induced @entity943 after a recent @entity583 , whereas @entity3303 may in some cases aggravate @entity943 .
